RxDoctor Payments Data

Juanita Hughes, DO

Family Medicine · Hazard, KYNPI 1467641944

Payments from drug & device makers

$710in general payments, 2019–2025

Across 43 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$205
  • Lilly USA, LLC$90
  • AbbVie$89
  • Corium, LLC$48
  • Bayer$34
  • Daiichi Sankyo Inc.$32
  • plus $210 from 12 others

What the payments were for

  • Food & beverage$65292%
  • Education$578%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$710 in reported general payments places this provider in the 50th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$13,015
Medicare patients
85
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$108,163
MounjaroTirzepatide94$96,501
FarxigaDapagliflozin Propanediol89$69,103
JardianceEmpagliflozin77$60,828
KerendiaFinerenone49$37,610
JanuviaSitagliptin Phosphate32$34,370
EliquisApixaban44$33,592
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$33,301
XareltoRivaroxaban26$27,050
VraylarCariprazine Hcl16$22,191
TrulicityDulaglutide12$20,416
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$19,901
LinzessLinaclotide36$19,201
BriviactBrivaracetam12$15,613
Tresiba Flextouch U-100Insulin Degludec15$13,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$90$116,917106 claims
Novo NordiskOzempic$18$108,163110 claims
Boehringer IngelheimJardiance, Tradjenta$15$72,04692 claims
AbbVieVraylar, Linzess$89$41,39252 claims
GSKTrelegy Ellipta, Anoro Ellipta$15$41,32062 claims
BayerKerendia$34$37,61049 claims
PfizerEliquis$205$33,59244 claims
Johnson & JohnsonXarelto$16$27,05026 claims
Hikma Pharmaceuticals USAEpinephrine$21$2,35011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Hazard

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →